Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Addendum to Project A24-85

Report documents

1. Addendum

   Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Addendum to Project A24-85

   published on

   15.04.2025

   Document type

   PDF document, 238 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G25-03_V1.1

   Download file : Addendum (PDF document, 238 kB, DE, not accessible)

Additional information

Project details

Project no.

G25-03

Commission

Commission awarded on 07.01.2025 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Head and nerves

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

The current version 1.1 of the addendum replaces version 1.0 published on Feb 20, 2025.

DOI

https://doi.org/10.60584/G25-03_V1.1

Connected Projects

1. Dossier assessment

   Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A24-85

   Last updated

   02.12.2024

   Status: Commission completed